Published in final edited form as:

J Clin Cell Immunol. ; 4: 160–. doi:10.4172/2155-9899.1000160.

Intracellular Signaling Pathways in Rheumatoid Arthritis

Charles J Malemud*

Arthritis Research Laboratory, Department of Medicine, Division of Rheumatic Diseases, Case Western Reserve University, School of Medicine and University Hospitals Case Medical Center, Cleveland, Ohio 44106, USA

Abstract

Dysfunctional intracellular signaling involving deregulated activation of the Janus Kinase/Signal Transducers and Activators of Transcription (JAK/STAT) and “cross-talk” between JAK/STAT and the stress-activated protein kinase/mitogen-activated protein kinase (SAPK/MAPK) and Phosphatidylinositol-3-Kinase/AKT/mammalian Target of Rapamycin (PI-3K/AKT/mTOR) pathways play a critical role in rheumatoid arthritis. This is exemplified by immune-mediated chronic inflammation, up-regulated matrix metalloproteinase gene expression, induction of articular chondrocyte apoptosis and “apoptosis-resistance” in rheumatoid synovial tissue. An important consideration in the development of novel therapeutics for rheumatoid arthritis will be the extent to which inhibiting these signal transduction pathways will sufficiently suppress immune cell-mediated inflammation to produce a lasting clinical remission and halt the progression of rheumatoid arthritis pathology. In that regard, the majority of the evidence accumulated over the past decade indicated that merely suppressing pro-inflammatory cytokine-mediated JAK/STAT, SAPK/MAPK or PI-3K/AKT/mTOR activation in RA patients may be necessary but not sufficient to result in clinical improvement. Thus, targeting aberrant enzyme activities of spleen tyrosine kinase, sphingosine kinases-1, -2, transforming growth factor β -activated kinase-1, bone marrow kinase, and nuclear factor- κ B-inducing kinase for intervention may also have to be considered.

Keywords

Apoptosis; Arthritis; Cartilage; Cell survival; Inflammation; Protein kinase; Signal transduction; Small molecule inhibitor; Synovium

Introduction

The concept was so elegant in its simplicity that (RA) [1] is available that it was surprising that directly targeting intracellular signaling pathways in arthritis to restore normalcy to dysfunctional immune-mediated Inflammation took so long to have finally reached the

Copyright: © 2013 Malemud CJ

*Corresponding author: Charles J. Malemud, Ph.D., Department of Medicine, Division of Rheumatic Diseases, University Hospitals Case Medical Center, Foley Medical Building, 2061 Cornell Road, Rm. 207, Cleveland, Ohio 44106-5076 USA, Tel: (216) 844-7846; Fax: (216) 844-2288; cjm4@cwru.edu.

The author declares no conflict of interest.

This article was originally published in a journal by OMICS Publishing Group, and the attached copy is provided by OMICS Publishing Group for the author's benefit and for the benefit of the author's institution, for commercial/research/educational use including without limitation use in instruction at your institution, sending it to specific colleagues that you know, and providing a copy to your institution's administrator.

All other uses, reproduction and distribution, including without limitation commercial reprints, selling or licensing copies or access, or posting on open internet sites, your personal or institution's website or repository, are requested to cite properly.

clinic. Now that the novel small molecule Janus Kinase-1, -3 (JAK1/3) inhibitor, tofacitinib, which was recently approved by the US Food & Drug Administration for the treatment of moderate-to-severe rheumatoid arthritis (RA) [1] is available for treating RA patients in the general population, it is likely that this monumental achievement in the development of an inhibitor that targets a specific class of protein kinases will further revolutionize the medical therapy of RA.

Drugs Employed in the Medical Therapy of RA

Presently tofacitinib is essentially restricted for use in RA patients who are unresponsive or have become refractory to therapy with conventional disease-modifying anti-rheumatic drugs (DMARDs) or to treatment with anti-rheumatic biological agents. The conventional DMARDs included in the pharmaceutical armamentarium for RA are corticosteroids, salicylates and non-steroidal anti-inflammatory drugs [2], anti-malarial drugs [3] methotrexate [2], and leflunomide [4]. Depending on whether or not RA patients demonstrate a clinically significant response to conventional DMARDs, RA patients may then also be treated with anti-rheumatic biological drugs. Included in this group are tumor necrosis factor (TNF) inhibitor monotherapy [5,6], TNF inhibitor in combination with methotrexate [4] or leflunomide [7], anti-IL-6-receptor binding inhibitor [8-11] or anti-IL-6 receptor binding inhibitor in combination with methotrexate [10,11], anti-IL-1 inhibitor [12,13], anti-T-cell [14,15] or anti-B-cell [16,17] biologicals. RA patients treated with tofacitinib plus methotrexate has also recently been reported [18].

The “Standard of Care” for RA Indicates that the Use of Multiple Biological Drugs is prohibited

At the present time, employing multiple biological drugs in a single RA patient is prohibited [19]. In addition, serious concerns continue to exist regarding long-term monotherapy with these biological drugs. RA patients are already known to be at higher risk for co-morbid conditions associated with their disease. Moreover, developing these co-morbidities appears to be independent of the defined risk factors for these conditions in the general population. Thus, long-term therapy with biological drugs may increase the relative risk to RA patients for developing serious infections [20-22], malignancies [20,23] as well as a worsening of cardiovascular disease, especially in those RA patients with pre-existing congestive heart failure [24]; the latter condition wherein therapy with biological drugs is contraindicated [25].

Future Drug Therapies for RA

An important concern in developing novel RA therapeutics going forward will be the extent to which inhibition of the JAK/Signal Transducers and Activators of Transcription (STAT) pathway alone will sufficiently suppress immune cell-mediated Inflammation to produce a lasting clinical remission. In that regard, the majority of the evidence now having been accumulated over the past decade indicated that merely suppressing pro-inflammatory cytokine-mediated JAK/STAT activation in RA patients may be necessary but not sufficient to result in clinical remission.

Personalized Molecular Medicine

Consistent with this view, we predict that the most efficient way for future RA drug development will be to focus on producing orally-administered SMIs with high selectivity and specificity for individual protein kinases. This paradigm could prove even more fruitful if a “personalized molecular medicine” approach was developed whereby the repertoire of

elevated pro-inflammatory cytokines in both the serum and synovial fluid of individual RA patients was completely defined prior to beginning drug therapy and a specific protein kinase SMI chosen on the basis of which cytokine and/or signaling pathway repertoire was involved.

In light of this contention, we recently suggested that dysfunctional intracellular signaling involving protein kinase pathways other than JAK/STAT as well as “cross-talk” between JAK/STAT and the stress-activated protein kinase/mitogen-activated protein kinase (SAPK/MAPK) and Phosphatidylinositol-3-Kinase/AKT/mammalian Target of Rapamycin (PI-3K/AKT/mTOR) pathways is likely to be required to completely dampen immune-mediated Inflammation and cartilage destruction in RA [26-28]. Supporting this viewpoint are the results of an analysis involving the therapy of active RA with the anti-IL-6 receptor inhibitor, tocilizumab [29]. Thus, in a random 90% sample of data from the ‘Tocilizumab Safety and the Prevention of Structural Joint Damage Study’ (LITHE) clinical trial of patients with active RA treated with methotrexate, the results revealed a surprisingly clear-cut dissociation between suppression of Inflammation induced by tocilizumab as measured by ‘The Genant-modified Sharp Score’ (‘TGSS’), simplified disease activity score index, swollen joint count and C-reactive protein levels which were all reduced from baseline in the tocilizumab-treated group, and evidence of synovial joint cartilage destruction, as measured by changes in joint space narrowing by X-ray analysis. These results also showed that RA patients achieving clinical remission by both objective and subjective criteria in the placebo or tocilizumab arm who had initial low disease scores, low ‘TGSS’, minimal bone erosion and near-normal joint space narrowing benefited more from treatment with tocilizumab or placebo than RA patients with higher initial disease activity scores in either the placebo or tocilizumab arm of this clinical trial. Therefore, when all of the data from clinical trials such as this one are combined with previously reported basic and clinical research data [26,27,30]. The results suggest that multiple drug treatment strategies may have to be considered in order to suppress the progression of articular cartilage damage in RA, which appears to result from a mechanism quite distinct from the one that regulates changes in biomarkers of Inflammation, bone erosion and cell survival.

Intracellular Signaling Regulates Immune-cell, Synoviocyte Survival, and Cartilage Apoptosis in RA

In addition to these above considerations, there is now mounting evidence that several protein kinases are deregulated in RA as well as in autoimmune disorders in general. Thus, dysfunctional intracellular signaling induced by pro-inflammatory cytokines was shown to be responsible for aberrant immune-cell survival [31-33], articular chondrocyte apoptosis [33,34] and/or “apoptosis-resistance” of cells in RA synovial tissue [35-38]. Abnormalities in the aforementioned JAK/STAT, SAPK/MAPK and PI-3K/AKT/mTOR pathways [26,27,39-41] as well as aberrant activities in spleen tyrosine kinase (Syk) [42-46], the sphingosine kinases, SphK1 and SphK2 [47-52], transforming growth factor β -activated kinase-1 (TAK1) [53], bone marrow kinase (BMX) [54] and nuclear factor- κ B-inducing kinase (NIK) [55] have all been found in patients with active RA. To illustrate this point, Gottar-Guillier et al. [54] showed that BMX activity was a requirement for p38 kinase and JNK phosphorylation as well as for the activation of NF- κ B [55]. Therefore BMX may be responsible for regulating the activation of p38, JNK and NF- κ B, all of which are critical to the inflammatory response cell survival and apoptosis.

Thus, over-expression of protein kinase genes or changes in protein kinase activity would result in, or promote exuberant cell survival and/ or resistance to apoptosis, or both. Of note, SMIs for a few of these protein kinases are already in development for the therapy of RA [51,56,57].

Which Pro-Inflammatory Cytokines are Elevated in the Sera and Synovial Fluids of RA Patients?

There is now persuasive evidence that the level of a particular pro-inflammatory cytokine in sera and synovial fluid reflects their role in the pathogenesis and progression of RA. Thus, TNF- α and several of the interleukins (IL), including, IL-1, -6, -7, -8, -12/23, -15, -17, -18, -32, -35 and proteins of the interferon (INF) family were found to be elevated in RA sera [58-64] with a matching elevated repertoire of these cytokines in RA synovial fluid [28,65-69]. Of note, the cytokines produced by the T_H2 subset, identified by the expression of the GATA-3 transcription factor, which drives production of the anti-inflammatory cytokines, IL-4, -5 and -13, were found at reduced levels in RA [70]. Therefore, based on these results it is tempting to design experimental strategies to rigorously define which of several possible intracellular signaling pathways are activated or suppressed by the biological activities of these elevated levels of pro-inflammatory cytokines. Likewise we can envision developing experimental systems to test the hypothesis that production of anti-inflammatory cytokines can be potentially increased by targeting activation of signaling cascades responsible for the expression of IL-4, -5, -13 and IL-10 genes.

Activation of the JAK/STAT Pathway

Activation of STAT proteins occurs after the interaction of pro-inflammatory, anti-inflammatory cytokines or growth factors with specific membrane-bound receptors on cells which results in JAK phosphorylation [71]. In this regard, STAT-responsive gene transcription is pertinent to perpetuating Inflammation and progression of RA joint destruction [71]. To summarize, the principal effects of JAK/STAT pathway activation by those pro-inflammatory cytokines which are present in elevated amounts in RA sera and synovial fluid, and including, IL-2, IL-3, and IL-19/IL-20, is to increase the gene expression of IL-2R, -3, -4, -6, gp130 (a component of the IL-6 trans-signaling complex), IL-10, -18R1, INF- γ , Oncostatin M (OSM) and TNF- α . Recent analyses have shown that IL-17A [72-74], IL-19 [75,76], and IL-20 also play an influential role in the context of JAK/STAT pathway activation [72,76] and in the progression of RA pathology which make these findings particularly noteworthy. In particular, Moran et al. [74] showed that IL-17A increased matrix metalloproteinase (MMP)-1, -2, -9, and -13 by RA synovial tissue explants, RA synovial fibroblast cultures, articular cartilage and cultured chondrocytes. This MMP repertoire was shown to be significant in driving the degradation of articular cartilage extracellular matrix (ECM) proteins in RA [77]. Moreover, together with OSM and TNF- α , treatment with IL-17A resulted in a skewing of the ratio of MMPs to tissue inhibitor of matrix metalloproteinases (TIMPs) favoring MMPs. However, cartilage explant ECM protein was only partially degraded in the presence of IL-17A, but when OSM and TNF- α was added, cartilage ECM protein degradation was complete. Interestingly, only 28% of those RA patients in this patient cohort had elevated levels of serum IL-17A prior to beginning biologic therapy. Of note, RA patients who were "IL-17A-negative" showed reduced ratios of MMP-1/TIMP-4, MMP3/TIMP-1 and MMP3/TIMP-4 after treatment with biological drugs, whereas "IL-17A positive" RA patients did not. At issue here is the extent to which OSM, TNF- α and IL-17A, alone, or in combination, activated JAK/STAT signaling [26-28,48,57,63,66,71,74] which is ultimately responsible for the destruction of articular cartilage ECM in RA and for joint failure. We could then ask; would inhibiting activation of specific STAT proteins suppress MMP gene expression and cartilage destruction?

SAPK/MAPK Pathway Activation

From a functional perspective the SAPK/MAPK signaling pathway is composed of the 5 p38 kinase isoforms, p38 α , p38 β 1, p38 β 2, p38 γ and p38 δ , extracellular signal-regulated protein kinases-1, -2, -3, -4, -7 (ERK-1, -2, -3, -4, -7) and C-Jun-N-terminal kinases, JNK1, JNK2 and JNK3 [78]. Complete activation of SAPK/MAPK signaling generally is dependent on the activity of upstream kinases, namely, MEK, MKK4 and MKKK7 [79], although there is some evidence that upstream kinase kinase-independent SAPK/MAPK activation can also occur [80].

A renewed focus on the role of the SAPK/MAPK signaling cascade in RA is driven by its significant role in regulating the cellular responsiveness to various pro-inflammatory cytokines including, MMP gene expression [40,81], NF- κ B activation [82], and cell survival and apoptosis [79,83]. However, inhibition of p38 α using an orally-administered SMI although showing promise in preclinical studies in animal models of RA [84] then failed to show efficacy in adult RA clinical trials [85]. This result may shift the focus of SMI research and development towards ERK 1/2 and JNK or to other components of SAPK/MAPK signaling implicated in the survival or apoptosis of immune-cells and activated synovocytes.

SAPK/MAPK Activation: Effects on Inhibitor of Apoptosis Proteins, IKK β , c-Myc and TNFR

Studies on the inhibitor of apoptosis proteins (IAP) have shown that they are critical regulators of immune-cell death in RA [31] as well as Inflammation in general [25]. With respect to defects in the innate immune system in RA, the activity of several pattern recognition receptors (PPRs) including, Toll-like receptor-4 (TLR4), nucleotide-binding oligomerization domain 1, (NOD1), nucleotide-binding oligomerization domain 2 (NOD2) receptors and retinoic acid-inducible gene (RIG-1) receptor were shown to be IAP-dependent [86]. Importantly, recent evidence showed that cellular-IAP1 (cIAP1), cIAP2 and X-chromosome-linked IAP (XIAP) (Figure 1), contained ubiquitin E3-ligase activity [87,88] and by this mechanism regulate p38, JNK and NF- κ B [89] activity and vice versa [90].

Interestingly, c-IAPs are required to recruit IKK β (Figure 1) the IKK regulatory subunit NF- κ B essential modulator (NEMO) and the RBCK1/Ho1l-interacting protein (HOIP) to the TNFR signaling complex. In turn, c-IAPs were shown to regulate TNF- α -mediated signaling [89] and downstream MAPK activation, including ERK-1, -2, the latter being important regulators of the biological activity of hemopoietic progenitor cells in RA synovium [91] and the oncoprotein transcription factor, c-Myc, by articular chondrocytes in response to mechanical stimulation which also involved integrin-linked kinase and B-Raf [92]. Over-expression of c-Myc is considered essential for maintaining the continuously proliferating phenotype of transformed cells [93], which is in all likelihood, a property relevant to the uncontrolled proliferation and the “apoptosis-resistant” phenotype of RA synovium [38].

Recent evidence also showed that the biological functions of c-Myc required that c-Myc form heterodimers with its activation partner, Max [93]. Importantly, the interaction between c-Myc and Max can be prevented with the small molecule, 7-nitro-N—(2-phenylphenyl)-2, 1, 3-benzoxadiazol-4-amine (10074-G5) which acts to distort the basic-helix-loop-helix leucine zipper protein domains in c-Myc the latter being the structural entity responsible for c-Myc/Max interactions [94]. Thus, regulating the biological activity of c-Myc could be facilitated by inhibiting ERK-1, -2. Conversely, suppressing the interaction of c-Myc with Max may also become a fruitful strategy for restoring normalcy to the aberrant proliferative phenotype of RA synovium [95].

Another signaling pathway critical for induction of apoptosis involves Fas ligand (FasL) and “the promoter of the death receptor,” Fas, also known as CD95, produced by monocyte-derived macrophages [96]. FasL binds to Fas and causes the recruitment of the Fas-activated death domain (FADD) protein (Figure 1) to the tumor necrosis factor receptor type 1-associated DEATH domain protein (TRADD) complex [30], activation of pro-caspase-8 and induction of apoptosis [30,31] via intranucleosomal DNA fragmentation (i.e. DNA degradation). Fas-like inhibitory protein (FLIP) (Figure 1) can block further downstream induction of apoptosis. Thus, cells which expressed high levels of FLIP had low “mature” caspase-8 activity [30,38].

Another potential strategy for suppressing Inflammation in RA and MAPK activation, in particular, may occur through manipulating the activation of TNFR complexes (Figure 1). In summary, TNFR complexes regulate the activation of the non-canonical NF- κ B pathway leading to translocation of c-IAPs, and TNF-associated factors- 2, -3 and -5 (TRAFs-2, -3 and -5) from the cytosol to the cell membrane and proteasomal or lysosomal-mediated degradation. In this manner, TRAFs are involved in multiple activation and inhibition signaling patterns [97], which regulate cellular recognition via their cytoplasmic interaction with other signaling molecules [98].

With respect to the role of TNFR1 in apoptosis, the binding of TNF- α to the Type I TNF receptor (TNFR1) triggers phosphorylation (P) by I κ B kinases of the inactive I κ B/RelA/p50 NF- κ B complex (Figure 1) with translocation of RelA/p65 and NFKB1/p50 to the nucleus. I κ B liberated from the inactive NF- κ B complex undergoes proteasomal-mediated degradation. NF- κ B-dependent apoptosis can be blocked by XIAP. As previously reported [99,100], XIAP was localized to both the cytoplasm and nucleus, but XIAP and another anti-apoptosis protein, survivin, were highly expressed in the cytoplasm of cells in active RA synovial tissue [101]. Second mitochondria-derived activator of caspase/direct inhibitor of apoptosis-binding protein with low pI (Smac/DIABLO) [38] mediated inhibition of XIAP activity may favor induction of apoptosis over cell survival under these conditions [31,38]. In addition, XIAP and other IAP proteins can directly inhibit caspase-3 and caspase-7 activity [102] as well as modulate the Bax/cytochrome C apoptosis pathway via XIAP-mediated inhibition of caspase-9 [103]. Thus, elevated levels of XIAP may be responsible for low caspase-3 activity and inhibition of apoptosis (i.e. “apoptosis-resistance”) in RA synovium [31].

PI-3K/AKT/mTOR Pathway Activation

The involvement of the PI-3K/AKT/mTOR pathway (Figure 1) in promoting aggressive immune-cell and synoviocyte proliferation and survival, neoangiogenesis, apoptosis, and altered innate immunity in inflammatory arthritis was recently reviewed [64]. The salient features of this review can be summarized as follows in which both positive and negative responses by cells involved in inflammatory arthritis were noted: 1) PI-3K/AKT/mTOR activity was associated with an increase in neutrophil, macrophage and eosinophil chemotaxis, mast cell degranulation, as well as activation, maturation and survival of activated T- and B-cells; 2) activation of PI-3K/AKT/mTOR by Tumor Necrosis-Related Apoptosis-Inducing Ligand (TRAIL) and IL-15 resulted in exuberant RA-fibroblast-like synoviocyte proliferation and increased IL-17 production by CD4⁺ T-cells, respectively; 3) conversely, activation of PI-3K/AKT/mTOR could also cause suppression of immune-cell proliferation by dampening Forkhead box protein O (FoxO) transcription factor activity; 4) resistance of RA synoviocytes to Fas (CD95)-induced apoptosis (Figure 1) involving activation of extracellular S1P via PI-3K/AKT/mTOR-dependent-SphK1; 5) Involvement of PI-3K/AKT/mTOR in innate immune responses pertinent to Inflammation was demonstrated

by the capacity of activated PI-3K/AKT/mTOR to dampen TLR4-mediated immune cell activity and regulation of peptidoglycan-induced IL-6 production in human synoviocytes.

In other studies, Cejka et al. [104] showed that inhibition of mTOR activity through treating human TNF-transgenic arthritic mice with sirolimus or everolimus inhibited osteoclast development, bone erosions and cartilage loss. Of interest, fewer bone-derived osteoclasts were found *ex vivo*, which was traced to induction of osteoclast apoptosis in mTOR inhibitor-treated TNF-transgenic arthritic mice. Importantly, a correlation was found between activated mTOR signaling and the number of osteoclasts in RA patients. The results of this study were supported by a proposal made by Kim et al. [105] who have asserted that mTOR activity was crucial for osteoclast survival. Thus, Kim et al. [105] contended that in RA patients combination therapy with an mTOR inhibitor and vitamin D(3) could effectively block subchondral bone erosion. Lastly, a recently discovered cytokine, IL-22, was shown to significantly increase the proliferation of fibroblasts isolated from the skin of patients with psoriatic arthritis [106]. Moreover, proliferation was effectively blocked by NVP-BEZ235, a dual inhibitor of PI-3K/ mTOR. The effect of NVP-BEZ235 was apparently dependent on AKT/ mTOR activity since IL-22 induced AKT and mTOR phosphorylation in these fibroblasts and in normal human epidermal keratinocytes.

The PI-3K/AKT/mTOR pathway can also be activated by growth factors (Figure 1) such as vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) both of which play significant roles in RA [107-109] because they can induce immune-cell, synoviocyte or chondrocyte apoptosis and/or survival which may be regulated by activation of cellular AKT [107,108]. Thus, the growth factor pathway cascade is initiated when VEGF or FGF interacts with their respective receptor tyrosine kinases resulting in activation of PI-3K γ , the intermediates phosphatidylinositol-phosphate-3 (PIP-3) and phosphoinositide-dependent protein kinase-1 (PDK-1) which then causes AKT1 activation [109]. Thus, when AKT1 is correctly oriented at the cell membrane through its capacity to bind to PIP-3, AKT1 is phosphorylated by its activating kinases, PDK-1 and mTOR complex 2 (mTORC2). In the context of RA, activated AKT1 phosphorylates several downstream signaling proteins resulting in up-regulation of mTOR and down-regulation of Glycogen Synthase Kinase-3 (GSK-3), FKHR, also known as Forkhead box protein O1, and Bad [110,111], the latter a member of BH3-interacting death-domain antagonist protein family [30], as well as other signaling proteins [112]. For example, AKT1 can differentially regulate the transcription of anti-apoptosis (i.e. survival pathway) genes such as 14-3-3 [113] and androgen receptor (AR) also known as nuclear receptor subfamily 3, group C, member 4 [114] or pro-apoptosis-related genes such as tumor protein-73 (TP-73) [115] which is structurally related to the p53 tumor protein.

Conclusions

The JAK1/3 SMI, tofacitinib, was recently developed for the treatment of moderate-to-severe cases of RA in patients who have inadequately responded to conventional DMARDs or therapy with anti-rheumatic biological drugs. The approval of tofacitinib appears to have provided the impetus for future basic research aimed at discovering novel protein kinase-specific SMIs which may be targeted towards individual protein kinases or targeted as a dual protein kinase inhibitor such as the newly described N1-p-fluorobenzyl-cymserine which was reported to inhibit both p38 kinase and JNK as well as NF- κ B [116].

In addition to the role played by pro-inflammatory cytokines in RA that cause deregulation of JAK/STAT [26-28] and SAPK/MAPK [117-121], the results of recent studies have focused on why the PI-3K/AKT/ mTOR signaling pathway (Figure 1) may be the most suitable target in the development of SMIs for RA [104-106]. Certainly, additional targets

for regulating abnormal JAK/STAT activity could also arise from a greater understanding of the negative regulators of JAK/STAT activation, including Suppressor of Cytokine Signaling (SOCS), protein phosphatases such as SHP-1, and Protein Inhibitor of Activated STAT (PIAS) proteins which are also significantly deregulated in RA [26]. Thus, along with the aforementioned protein kinases, Syk, SphK1 and SphK2, TAK1, BMX and NIK which were also identified as participants in the RA process these enzymes could all become suitable targets for future medical intervention in RA.

However, enthusiasm for developing SMIs for any one specific protein kinase implicated in the pathophysiology of RA must be tempered and viewed with cautious optimism as a result of the recent evidence from the OSKIRA-I Phase III safety and tolerability study [122]. As previously discussed, Syk is a suitable target for RA intervention. This is because activation of Syk occurs in response to B-cell antigen receptor (BCR) engagement [42-46]. As such, activation of the BCR and Syk activation downstream of the BCR regulates B-cell development, and survival. In OSKIRA-I, fostamatinib (formally known as R788), an orally administered Syk SMI, improved the clinical symptoms of 923 RA patients who had not adequately responded to methotrexate. However, this clinical response was seen only at the American College of Rheumatology-20 (ACR20) criteria. Importantly, fostamatinib failed to improve the modified Total Sharp Score when compared to placebo at 24 wks at either of the two doses employed. The most common side-effects of fostamatinib in OSKIRA-I were hypertension, diarrhea, nausea, headache and nasopharyngitis. However, the results of previous clinical studies had also shown that fostamatinib was associated with increased rates of infection, elevated liver enzyme levels and neutropenia [56]. Therefore, additional data will have to be collected over a longer period of observation in order to determine the extent to which fostamatinib can improve clinical outcomes in RA at least at the ACR50 level. Whether or not a positive clinical response to fostamatinib will correlate with a reduction in subchondral bone erosions and/or inhibition of articular cartilage destruction must also be considered in judging the effectiveness of fostamatinib as an RA therapy.

Acknowledgments

The Arthritis Research Laboratory (ARL) was supported by an investigator-initiated project grant from Takeda Pharmaceuticals of North American and is presently supported by a research contract from Genentech/Roche Group to CJM. The ARL is also supported by the Visual Sciences Research Center Core Grant, P30-EY11373, from the National Eye Institute. We thank Mr. Evan C. Meszaros, M.S. for helpful discussions and for rendering the information in Figure 1.

References

1. Zerbini CA, Lomonte AB. Tofacitinib for the treatment of rheumatoid arthritis. *Expert Rev Clin Immunol.* 2012; 8:319–331. [PubMed: 22607178]
2. Upchurch KS, Kay J. Evolution of treatment for rheumatoid arthritis. *Rheumatology (Oxford).* 2012; 51(6):vi28–vi36. [PubMed: 23221584]
3. Taherian E, Rao A, Malemud CJ, Askari A. The biological and clinical activity of anti-malarial drugs in autoimmune disorders. *Curr Rheum Rev.* 2013; 9:45–62.
4. Finckh A, Dehler S, Gabay C, SCQM doctors. The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study. *Ann Rheum Dis.* 2009; 68:33–39. [PubMed: 18230627]
5. Taylor PC. Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases. *Curr Opin Pharmacol.* 2010; 10:308–315. [PubMed: 20172761]
6. Salliot C, Finckh A, Katchamart W, Lu Y, Sun Y, et al. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis. *Ann Rheum Dis.* 2011; 70:266–271. [PubMed: 21097801]

7. De Stefano R, Frati E, Nargi F, Baldi C, Menza L, et al. Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti-TNF-alpha versus methotrexate-anti-TNF-alpha. *Clin Rheumatol*. 2010; 29:517–524. [PubMed: 20082236]
8. Ogata A, Hirano T, Hishitani Y, Tanaka T. Safety and efficacy of tocilizumab for the treatment of rheumatoid arthritis. *Clin Med Insights Arthritis Musculoskelet Disord*. 2012; 5:27–42. [PubMed: 22438671]
9. Tanaka T, Kishimoto T. Immunotherapy of tocilizumab for rheumatoid arthritis. *J Clin Cell Immunol*. 2013; S6:001.
10. Navarro-Millán I, Singh JA, Curtis JR. Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor. *Clin Ther*. 2012; 34:788–802. [PubMed: 22444783]
11. Dougados M, Kissel K, Sheeran T, Tak PP, Conaghan PG, et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). *Ann Rheum Dis*. 2013; 72:43–50. [PubMed: 22562983]
12. Mertens M, Singh JA. Anakinra for rheumatoid arthritis: a systematic review. *J Rheumatol*. 2009; 36:1118–1125. [PubMed: 19447938]
13. Geyer M, Müller-Ladner U. Actual status of antiinterleukin-1 therapies in rheumatic diseases. *Curr Opin Rheumatol*. 2010; 22:246–251. [PubMed: 20150813]
14. Östör AJ. Abatacept: a T-cell co-stimulation modulator for the treatment of rheumatoid arthritis. *Clin Rheumatol*. 2008; 27:1343–1353. [PubMed: 18670735]
15. Daridon C, Youinou P, Pers JO. BAFF, APRIL, TWE-PRIL: who's who? *Autoimmun Rev*. 2008; 7:267–271. [PubMed: 18295728]
16. Jacobi AM, Dörner T. Current aspects of anti-CD20 therapy in rheumatoid arthritis. *Curr Opin Pharmacol*. 2010; 10:316–321. [PubMed: 20189875]
17. Bracewell C, Isaacs JD, Emery P, Ng WF. Atacicept, a novel B cell-targeting biological therapy for the treatment of rheumatoid arthritis. *Expert Opin Biol Ther*. 2009; 9:909–919. [PubMed: 19522556]
18. van der Heijde D, Tanaka Y, Fleischmann R, Keystone E, Kremer J, et al. Tofacitinib (CP690,550) in patients with rheumatoid arthritis receiving methotrexate. Twelve-month data from a twenty-four-month phase III randomized radiographic study. *Arthritis Rheum*. 2013; 65:559–570. [PubMed: 23348607]
19. Kiely PD, Deighton C, Dixey J, Östör AJ, British Society for Rheumatology Standards, Guidelines and Audit Working Group. Biological agents for rheumatoid arthritis—negotiating the NICE technology appraisals. *Rheumatology (Oxford)*. 2012; 51:24–31. [PubMed: 22039226]
20. Keystone EC. Does anti-tumor necrosis factor- α therapy affect risk of serious infection and cancer in patients with rheumatoid arthritis?: a review of longterm data. *J Rheumatol*. 2011; 38:1552–1562. [PubMed: 21572154]
21. Campbell L, Chen C, Bhagat SS, Parker RA, Östör AJ. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. *Rheumatology (Oxford)*. 2011; 50:552–562. [PubMed: 21078627]
22. Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. *Rheumatology (Oxford)*. 2013; 52:53–61. [PubMed: 23192911]
23. Khraishi M. Comparative overview of safety of the biologics in rheumatoid arthritis. *J Rheumatol Suppl*. 2009; 82:25–32. [PubMed: 19509327]
24. Nurmohamed MT, van Halm VP, Dijkmans BA. Cardiovascular risk profile of antirheumatic agents in patients with osteoarthritis and rheumatoid arthritis. *Drugs*. 2002; 62:1599–1609. [PubMed: 12109923]
25. Cacciapaglia F, Navarini L, Menna P, Salvatorelli E, Minotti G, et al. Cardiovascular safety of anti-TNF-alpha therapies: facts and unsettled issues. *Autoimmun Rev*. 2011; 10:631–635. [PubMed: 21539939]
26. Malemud CJ, Pearlman E. Targeting JAK/STAT signaling pathway in inflammatory diseases. *Curr Signal Transduct Ther*. 2009; 4:201–221.

27. Malemud CJ. Differential activation of JAK enzymes in rheumatoid arthritis and autoimmune disorders by proinflammatory cytokines–potential drug targets. *Int J Interferon Cytokine Mediator Res.* 2010; 2:97–111.
28. Malemud CJ. Dysfunctional immune-mediated Inflammation in rheumatoid arthritis dictates that development of anti-rheumatic disease drugs target multiple intracellular signaling pathways. *Anti-Inflammatory Anti-Allergy Agents Med Chem.* 2011; 10:78–84.
29. Smolen JS, Avila JC, Aletaha D. Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between Inflammation and destruction. *Ann Rheum Dis.* 2012; 71:687–693. [PubMed: 22121130]
30. Malemud CJ, Gillespie HJ. The role of apoptosis in arthritis. *Curr Rheum Rev.* 2005; 1:131–142.
31. Lewis AC, Malemud CJ. Correction of dysfunctional apoptosis in arthritis by pharmacologic intervention: Focus on altering the activity of inhibitor of apoptosis proteins. *Recent Res Devel Pharmacol.* 2011; 2:69–84.
32. Mayer BA, Rehberg M, Erhardt A, Wolf A, Reichel CA, et al. Inhibitor of apoptosis proteins as novel targets in inflammatory processes. *Arterioscler Thromb Vasc Biol.* 2011; 31:2240–2250. [PubMed: 21817100]
33. Caramés B, López-Armada MJ, Cillero-Pastor B, Lires-Dean M, Vaamonde C, et al. Differential effects of tumor necrosis factor- α and interleukin-1 β on cell death in human articular chondrocytes. *Osteoarthritis Cartilage.* 2008; 16:715–722. [PubMed: 18054255]
34. Malemud CJ, Sun Y, Pearlman E, Ginley N, Awadallah A, et al. Monosodium urate and tumor necrosis factor- α increase apoptosis in human chondrocyte cultures. *Rheumatol Curr Res.* 2012; 2:113.
35. Liu H, Pope RM. Apoptosis in rheumatoid arthritis: friend or foe. *Rheum Dis Clin North Am.* 2004; 30:603–625. [PubMed: 15261344]
36. Jonsson H, Allen P, Peng SL. Inflammatory arthritis requires Foxo3a to prevent Fas ligand-induced neutrophil apoptosis. *Nat Med.* 2005; 11:666–671. [PubMed: 15895074]
37. Korb A, Pavenstädt H, Pap T. Cell death in rheumatoid arthritis. *Apoptosis.* 2009; 14:447–454. [PubMed: 19199037]
38. Malemud CJ. Apoptosis resistance in rheumatoid arthritis synovial tissue. *J Clin Cell Immunol.* 2011; S3:0061.
39. Asquith DL, McInnes IB. Emerging cytokine targets in rheumatoid arthritis. *Curr Opin Rheumatol.* 2007; 19:246–251. [PubMed: 17414950]
40. Malemud CJ, Reddy SK. Targeting cytokines, chemokines and adhesion molecules in rheumatoid arthritis. *Curr Rheum Res.* 2008; 4:219–234.
41. Wu T, Mohan C. The AKT axis as a therapeutic target in autoimmune diseases. *Endocr Metab Immune Disord Drug Targets.* 2009; 9:145–150. [PubMed: 19519464]
42. Kulathu Y, Grothe G, Reth M. Autoinhibition and adapter function of Syk. *Immunol Rev.* 2009; 232:286–299. [PubMed: 19909371]
43. Geahlen RL. Syk and pTyr'd: Signaling through the B cell antigen receptor. *Biochim Biophys Acta.* 2009; 1793:1115–1127. [PubMed: 19306898]
44. Riccaboni M, Bianchi I, Petrillo P. Spleen tyrosine kinases: biology, therapeutic targets and drugs. *Drug Discov Today.* 2010; 15:517–530. [PubMed: 20553955]
45. Ghosh D, Tsokos GC. Spleen tyrosine kinase: an Src family of non-receptor kinase has multiple functions and represents a valuable therapeutic target in the treatment of autoimmune and inflammatory diseases. *Autoimmunity.* 2010; 43:48–55. [PubMed: 20001666]
46. Coffey G, DeGuzman F, Inagaki M, Pak Y, Delaney SM, et al. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and Inflammation in animal models of rheumatoid arthritis. *J Pharmacol Exp Ther.* 2012; 340:350–359. [PubMed: 22040680]
47. Melendez AJ. Sphingosine kinase signalling in immune cells: potential as novel therapeutic targets. *Biochim Biophys Acta.* 2008; 1784:66–75. [PubMed: 17913601]
48. Malemud CJ. The discovery of novel experimental therapies for inflammatory arthritis. *Mediators Inflamm.* 2009; 2009:698769. [PubMed: 20339519]

49. Lai WQ, Melendez AJ, Leung BP. Role of sphingosine kinase and sphingosine-1-phosphate in inflammatory arthritis. *World J Biol Chem.* 2010; 1:321–326. [PubMed: 21537466]
50. Chi H. Sphingosine-1-phosphate and immune regulation: trafficking and beyond. *Trends Pharmacol Sci.* 2011; 32:16–24. [PubMed: 21159389]
51. Edmonds Y, Milstien S, Spiegel S. Development of small-molecule inhibitors of sphingosine-1-phosphate signaling. *Pharmacol Ther.* 2011; 132:352–360. [PubMed: 21906625]
52. Lai WQ, Chia FL, Leung BP. Sphingosine kinase and sphingosine-1-phosphate receptors: novel therapeutic targets of rheumatoid arthritis? *Future Med Chem.* 2012; 4:727–733. [PubMed: 22530637]
53. Dai L, Aye Thu C, Liu XY, Xi J, Cheung PC. TAK1, more than just innate immunity. *IUBMB Life.* 2012; 64:825–834. [PubMed: 22941947]
54. Gottar-Guillier M, Dodeller F, Huesken D, Iourgenko V, Mickanin C, et al. The tyrosine kinase BMX is an essential mediator of inflammatory arthritis in a kinase-independent manner. *J Immunol.* 2011; 186:6014–6023. [PubMed: 21471444]
55. Razani B, Reichardt AD, Cheng G. Non-canonical NF- κ B signaling activation and regulation: principles and perspectives. *Immunol Rev.* 2011; 244:44–54. [PubMed: 22017430]
56. Kyttaris VC. Kinase inhibitors: a new class of antirheumatic drugs. *Drug Des Devel Ther.* 2012; 6:245–250.
57. Fleischmann R. Novel small-molecular therapeutics for rheumatoid arthritis. *Curr Opin Rheumatol.* 2012; 24:335–341. [PubMed: 22357358]
58. Szekanecz Z, Koch AE. Macrophages and their products in rheumatoid arthritis. *Curr Opin Rheumatol.* 2007; 19:289–295. [PubMed: 17414958]
59. Furuzawa-Carballeda J, Vargas-Rojas MI, Cabral AR. Autoimmune Inflammation from the Th17 perspective. *Autoimmun Rev.* 2007; 6:169–175. [PubMed: 17289553]
60. Cope AP, Schulze-Koops H, Aringer M. The central role of T cells in rheumatoid arthritis. *Clin Exp Rheumatol* 5 Supl. 2007; 46:S4–11.
61. Bugatti S, Codullo V, Caporali R, Montecucco C. B cells in rheumatoid arthritis. *Autoimmun Rev.* 2007; 6:482–487. [PubMed: 17643937]
62. Lotito AP, Silva CA, Mello SB. Interleukin-18 in chronic joint diseases. *Autoimmun Rev.* 2007; 6:253–256. [PubMed: 17317618]
63. Malemud CJ. Recent advances in neutralizing the IL-6 pathway in arthritis. *Open Access Rheumatology: Research and Reviews.* 2009; 1:133–150.
64. Wisler BA, Dennis JE, Malemud CJ. New organ-specific pharmacological strategies interfering with signaling pathways in inflammatory disorders/ autoimmune disorders. *Curr Signal Transduct Ther.* 2011; 6:279–291.
65. Hartgring SA, Bijlsma JW, Lafeber FP, van Roon JA. Interleukin-7 induced immunopathology in arthritis. *Ann Rheum Dis.* 2006; 65(3):iii69–74. [PubMed: 17038478]
66. Petrovic-Rackov L, Pejnovic N. Clinical significance of IL-18, IL-15, IL-12 and TNF-alpha measurement in rheumatoid arthritis. *Clin Rheumatol.* 2006; 25:448–452. [PubMed: 16362448]
67. Joosten LA, Netea MG, Kim SH, Yoon DY, Oppers-Walgreen B, et al. IL-32, a proinflammatory cytokine in rheumatoid arthritis. *Proc Natl Acad Sci U S A.* 2006; 103:3298–3303. [PubMed: 16492735]
68. Collison LW, Workman CJ, Kuo TT, Boyd K, Wang Y, et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. *Nature.* 2007; 450:566–569. [PubMed: 18033300]
69. Boniface K, Blom B, Liu YJ, de Waal Malefyt R. From interleukin-23 to T-helper 17 cells: human T-helper cell differentiation revisited. *Immunol Rev.* 2008; 226:132–146. [PubMed: 19161421]
70. DiPlacido LD, Craft J. Emerging from the shadows: follicular helper T cells in autoimmunity. *Arthritis Rheum.* 2010; 62:6–8. [PubMed: 20039423]
71. Malemud, CJ. Suppression of pro-inflammatory cytokines via targeting of STAT-responsive genes. In: El-Shemy, H., editor. *Drug Discovery.* InTech Publishing; Rijeka, Croatia: 2013. p. 373-411.
72. Paunovic V, Carroll HP, Vandenbroeck K, Gadina M. Signalling, Inflammation and arthritis: crossed signals: the role of interleukin (IL)-12, -17, -23 and -27 in autoimmunity. *Rheumatology (Oxford).* 2008; 47:771–776. [PubMed: 18238793]

73. Astry B, Harberts E, Moudgil KD. A cytokine-centric view of the pathogenesis and treatment of autoimmune arthritis. *J Interferon Cytokine Res.* 2011; 31:927–940. [PubMed: 22149412]
74. Moran EM, Mullan R, McCormick J, Connolly M, Sullivan O, et al. Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumor necrosis factor- α , Oncostatin M and response to biologic therapies. *Arthritis Res Ther.* 2009; 11:R113. [PubMed: 19627579]
75. Azuma YT, Nakajima H, Takeuchi T. IL-19 as a potential therapeutic in autoimmune and inflammatory diseases. *Curr Pharm Des.* 2011; 17:3776–3780. [PubMed: 22103848]
76. Leng RX, Pan HF, Tao JH, Ye DQ. IL-19, IL-20 and IL-24: potential therapeutic targets for autoimmune diseases. *Expert Opin Ther Targets.* 2011; 15:119–126. [PubMed: 21073280]
77. Malemud, CJ. Regulation of chondrocyte matrix metalloproteinase gene expression. In: Dhalla, NS.; Chakraborti, S., editors. *Role of Proteases in Cellular Dysfunction.* Springer Science; UK: 2013.
78. Malemud CJ, Miller AH. Pro-inflammatory cytokine-induced SAPK/ MAPK and JAK/STAT in rheumatoid arthritis and the new anti-depression drugs. *Expert Opin Ther Targets.* 2008; 12:171–183. [PubMed: 18208366]
79. Chang L, Karin M. Mammalian MAP kinase signalling cascades. *Nature.* 2001; 410:37–40. [PubMed: 11242034]
80. Schlesinger TK, Fanger GR, Yujiri T, Johnson GL. The TAO of MEKK. *Front Biosci.* 1998; 3:D1181–1186. [PubMed: 9820741]
81. Burrage PS, Mix KS, Brinckerhoff CE. Matrix metalloproteinases: role in arthritis. *Front Biosci.* 2006; 11:529–543. [PubMed: 16146751]
82. Roman-Blas JA, Jimenez SA. NF-kappaB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis. *Osteoarthritis Cartilage.* 2006; 14:839–848. [PubMed: 16730463]
83. Aggarwal BB. Tumour necrosis factors receptor associated signalling molecules and their role in activation of apoptosis, JNK and NF-kappaB. *Ann Rheum Dis.* 2000; 59(1):i6–16. [PubMed: 11053079]
84. Ivanenkov YA, Balakin KV, Tkachenko SE. New approaches to the treatment of inflammatory disease : focus on small-molecule inhibitors of signal transduction pathways. *Drugs R D.* 2008; 9:397–434. [PubMed: 18989991]
85. Malemud CJ. Targeted drug development for arthritis. *Future Med Chem.* 2012; 4:701–703. [PubMed: 22530633]
86. Damgaard RB, Gyrð-Hansen M. Inhibitor of apoptosis (IAP) proteins in regulation of Inflammation and innate immunity. *Discov Med.* 2011; 11:221–231. [PubMed: 21447281]
87. Lopez J, Meier P. To fight or die - inhibitor of apoptosis proteins at the crossroad of innate immunity and death. *Curr Opin Cell Biol.* 2010; 22:872–881. [PubMed: 20888210]
88. Beug ST, Cheung HH, LaCasse EC, Korneluk RG. Modulation of immune signalling by inhibitors of apoptosis. *Trends Immunol.* 2012; 33:535–545. [PubMed: 22836014]
89. Fulda S, Vucic D. Targeting IAP proteins for therapeutic intervention in cancer. *Nat Rev Drug Discov.* 2012; 11:109–124. [PubMed: 22293567]
90. Nishikori M. Classical and alternative NF- κ B activation pathways and their roles in lymphoid malignancies. *J Clin Exp Histopathol.* 2005; 45:15–24.
91. Varfolomeev E, Goncharov T, Maecker H, Zobel K, Kömüves LG, et al. Cellular inhibitors of apoptosis are global regulators of NF- κ B and MAPK activation by members of the TNF family of receptors. *Sci Signal.* 2012; 5:ra22. [PubMed: 22434933]
92. Colmegna I, Pryshchep S, Oishi H, Goronzy JJ, Weyand CM. Dampened ERK signaling in hematopoietic progenitor cells in rheumatoid arthritis. *Clin Immunol.* 2012; 143:73–82. [PubMed: 22342385]
93. Perera PM, Wypasek E, Madhavan S, Rath-Deschner B, Liu J, et al. Mechanical signals control SOX9, VEGF, and c-Myc expression and cell proliferation during Inflammation via integrin-linked kinase, B-Raf, and ERK 1/2-dependent signaling in articular chondrocytes. *Arthritis Res Ther.* 2010; 12:R106. [PubMed: 20509944]

94. Clausen DM, Guo J, Parise RA, Beumer JH, Egorin MJ, et al. In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of 10074-G5, a novel small-molecule inhibitor of c-Myc/Max dimerization. *J Pharmacol Exp Ther.* 2010; 335:715–727. [PubMed: 20801893]
95. Berg T. Small-molecule modulators of c-Myc/Max and Max/Max interactions. *Curr Top Microbiol Immunol.* 2011; 348:139–149. [PubMed: 20680803]
96. Kiener PA, Davis PM, Starling GC, Mehlin C, Klebanoff SJ, et al. Differential induction of apoptosis by Fas-Fas ligand interactions in human monocytes and macrophages. *J Exp Med.* 1997; 185:1511–1516. [PubMed: 9126933]
97. Bishop GA, Xie P. Multiple roles of TRAF3 signaling in lymphocyte function. *Immunol Res.* 2007; 39:22–32. [PubMed: 17917053]
98. Hildebrand JM, Yi Z, Buchta CM, Poovassery J, Stunz LL, et al. Roles of tumor necrosis factor receptor associated factor 3 (TRAF3) and TRAF5 in immune cell functions. *Immunol Rev.* 2011; 244:55–74. [PubMed: 22017431]
99. Wang Y, Chan S, Tsang BK. Involvement of inhibitory nuclear factor- κ B (NF κ B)-independent NF κ B activation in the gonadotropic regulation of X-linked inhibitor of apoptosis expression during ovarian follicular development in vitro. *Endocrinology.* 2002; 143:2732–2740. [PubMed: 12072408]
100. Russell JC, Whiting H, Szufliata N, Hossain MA. Nuclear translocation of X-linked inhibitor of apoptosis (XIAP) determines cell fate after hypoxia ischemia in neonatal brain. *J Neurochem.* 2008; 106:1357–1370. [PubMed: 18485100]
101. Dharmapatri AA, Smith MD, Findlay DM, Holding CA, Evdokiou A, et al. Elevated expression of caspase-3 inhibitors, survivin and XIAP correlates with low levels of apoptosis in active rheumatoid synovium. *Arthritis Res Ther.* 2009; 11:R13. [PubMed: 19171073]
102. Deveraux QL, Takahashi R, Salvesen GS, Reed JC. X-linked IAP is a direct inhibitor of cell-death proteases. *Nature.* 1997; 388:300–304. [PubMed: 9230442]
103. Deveraux QL, Roy N, Stennicke HR, Van Arsdale T, Zhou Q, et al. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. *EMBO J.* 1998; 17:2215–2223. [PubMed: 9545235]
104. Cejka D, Hayer S, Niederreiter B, Sieghart W, Fuereder T, et al. Mammalian target of rapamycin signaling is crucial for joint destruction in experimental arthritis and is activated in osteoclasts from patients with rheumatoid arthritis. *Arthritis Rheum.* 2010; 62:2294–2302. [PubMed: 20506288]
105. Kim TH, Choi SJ, Lee YH, Song GG, Ji JD. Combined therapeutic application of mTOR inhibitor and vitamin D(3) for inflammatory bone destruction of rheumatoid arthritis. *Med Hypotheses.* 2012; 79:757–760. [PubMed: 22967804]
106. Mitra A, Raychaudhuri SK, Raychaudhuri SP. IL-22 induced cell proliferation is regulated by PI3K/Akt/mTOR signaling cascade. *Cytokine.* 2012; 60:38–42. [PubMed: 22840496]
107. Nishi J, Minamino T, Miyauchi H, Nojima A, Tateno K, et al. Vascular endothelial growth factor receptor-1 regulates postnatal angiogenesis through inhibition of the excessive activation of Akt. *Circ Res.* 2008; 103:261–268. [PubMed: 18583712]
108. Mavila N, James D, Utley S, Cu N, Coblens O, et al. Fibroblast growth factor receptor-mediated activation of AKT-beta-catenin-CBP pathway regulates survival and proliferation of murine hepatoblasts and hepatic tumor initiating stem cells. *PLoS One.* 2012; 7:e50401. [PubMed: 23308088]
109. Malemud CJ. Growth hormone, VEGF and FGF: involvement in rheumatoid arthritis. *Clin Chim Acta.* 2007; 375:10–19. [PubMed: 16893535]
110. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. *Science.* 2005; 307:1098–1101. [PubMed: 15718470]
111. Wylie MA, Malemud CJ. Deregulation of apoptosis in arthritis by altered signal transduction. *Int J Clin Rheumatol.* 2013; 8:483–490.
112. Beier F, Loeser RF. Biology and pathology of Rho GTPase, PI-3 kinase-Akt, and MAP kinase signaling pathways in chondrocytes. *J Cell Biochem.* 2010; 110:573–580. [PubMed: 20512918]
113. Mhawech P. 14-3-3 proteins--an update. *Cell Res.* 2005; 15:228–236. [PubMed: 15857577]

114. Heemers HV, Tindall DJ. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. *Endocr Rev.* 2007; 28:778–808. [PubMed: 17940184]
115. Ramadan S, Terrinoni A, Catani MV, Sayan AE, Knight RA, et al. p73 induces apoptosis by different mechanisms. *Biochem Biophys Res Commun.* 2005; 331:713–717. [PubMed: 15865927]
116. Batool S, Nawaz MS, Greig NH, Rehan M, Kamal MA. Molecular interaction study of N1-p-fluorobenzyl-cymserine with TNF-alpha, p38 kinase and JNK kinase. *Anti-Inflamm Anti-Allergy Agents Med Chem.* 2013; 12:129–135.
117. Malemud CJ. Small molecular weight inhibitors of stress-activated and mitogen-activated protein kinases. *Mini Rev Med Chem.* 2006; 6:689–698. [PubMed: 16787380]
118. Karouzakis E, Neidhart M, Gay RE, Gay S. Molecular and cellular basis of rheumatoid joint destruction. *Immunol Lett.* 2006; 106:8–13. [PubMed: 16824621]
119. Malemud CJ. Inhibitors of stress-activated protein/mitogen-activated protein kinase pathways. *Curr Opin Pharmacol.* 2007; 7:339–343. [PubMed: 17398158]
120. Malemud, CJ. MAP kinases. In: Buckwalter, J.; Lotz, M.; Stoltz, JF., editors. *OA, Inflammation and Degradation: A Continuum Biomedical and Health Research.* Amsterdam: 2007. p. 99-117. IOS Press
121. Malemud CJ. Immunotherapies and rheumatoid arthritis-Introduction. *J Clin Cell Immunol.* 2013; S6:e001.
122. AstraZeneca announces top-line results from OSKIRA-1 Phase III study of fostamatinib in rheumatoid arthritis.

Figure 1. An Apoptotic/Survival Cascade in Synovial Fibroblasts: Regulation via Fas (CD95), TNF- α and Growth Factor Receptors

Apoptosis or survival of synovial fibroblasts can be induced by several types of ligand-receptor interactions. These interactions may involve Fas, cytokine or growth factor receptor activation. P, site for MAPK-mediated phosphorylation.